Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: A propensity analysis

JAMA

Volumn 286, Issue 10, 2001, Pages 1187-1194

  Gum, Patricia A ^a   Thamilarasan, Maran ^a   Watanabe, Junko ^a   Blackstone, Eugene H ^a   Lauer, Michael S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; VERAPAMIL;

ADULT; AGING; ARTICLE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG USE; EXERCISE; EXERCISE TEST; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; STRESS ECHOCARDIOGRAPHY;

EID: 0035850414     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.10.1187     Document Type: Article

References (49)

1. Final report on the aspirin component of the ongoing Physicians' Health Study
2. Collaborative overview of randomised trials of antiplatelet therapy, I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
4. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease
5. Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease
6. Aspirin and the treatment of heart failure in the elderly
7. Invited commentary: Propensity scores
8. Association of chronotropic incompetence with echocardiographic ischemia and prognosis
9. Heart rate recovery and treadmill exercise score as predictors of mortality in patients referred for exercise ECG
10. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNCV)
11. Identification of severe coronary artery disease using simple clinical parameters
12. ACC/AHA Guidelines for Exercise Testing: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing)
13. Importance of estimated functional capacity as a predictor of all-cause mortality among patients referred for exercise thallium single-photon emission computed tomography: Report of 3,400 patients from a single center
14. Impaired chronotropic response to exercise stress testing as a predictor of mortality
15. Heart-rate recovery immediately after exercise as a predictor of mortality
16. Cause of death in clinical research: Time for a reassessment?
17. National sources of vital status information: Extent of coverage and possible selectivity in reporting
18. Use of commercial record linkage software and vital statistics to identify patient deaths
19. Regression models and life tables
20. Nonparametric estimation from incomplete observations
21. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information
22. Two internal thoracic artery grafts are better than one
23. Effect of strenuous exercise on platelet activation state and reactivity
24. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk
25. A prospective study of aspirin use and primary prevention of cardiovascular disease in women
26. Randomised trial of prophylactic daily aspirin in British male doctors
27. Low-dose aspirin therapy for chronic stable angina: A randomized, placebo-controlled clinical trial
28. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
29. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
30. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Cooperative Study
31. Aspirin, sulfinpyrazone, or both in unstable angina: Results of a Canadian multicenter trial
32. Aspirin, heparin, or both to treat acute unstable angina
33. Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice
34. Measuring effects without randomized trials? Options, problems, challenges
35. Cardiac presentation of non-Hodgkin's lymphoma
36. Self-selected posttrial aspirin use and subsequent cardiovascular disease and mortality in the Physicians' Health Study
37. 2 and prostacyclin
38. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA
39. Platelet hyperreactivity and prognosis in survivors of myocardial infarction
40. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin
41. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty
42. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
43. Randomized trials or observational tribulations?
44. Randomized, controlled trials, observational studies, and the hierarchy of research designs
45. A comparison of observational studies and randomized, controlled trials
46. Primary angioplasty: Time is of the essence
47. The environment and disease: Association or causation?
48. Platelet activity and phosphoinositide turnover increase with advancing age